This pathophysiology diagram illustrates the development and mechanism of a drug co-delivery system using poly(lactic-co-glycolic acid) (PLGA) nanoparticles for pain and inflammation management. The flowchart details the formulation process where diclofenac (Dic) and dexamethasone (Dex) are combined to form a Dic-Dex complex, which is then encapsulated into PLGA nanoparticles via nanoprecipitation. The resulting Dic-Dex-PLGA nanoparticles are administered through intraperitoneal injection, as demonstrated in a murine model. An inset diagram explains the in vivo pharmacological mechanism: the breaking of ester bonds releases the active Dic and Dex molecules, which subsequently inhibit cyclooxygenase-2 (COX-2) and arachidonic acid pathways. This molecular inhibition leads to a downregulation of pro-inflammatory mediators, specifically tumor necrosis factor-alpha (TNF-̑) and prostaglandin E (PGE), culminating in the clinical outcomes of reduced inflammation and pain relief. The diagram highlights the educational focus on nanotechnology-based drug delivery systems and the synergistic effects of combining nonsteroidal anti-inflammatory drugs (NSAIDs) with corticosteroids.

A pathophysiology diagram illustrating the molecular signaling pathway of arachidonic acid (AA) metabolism and its modulation by the natural compounds Betulin (B) and Betulinic Acid (BA). The primary pathway shows AA converting to Prostaglandin (PGH2) via Cyclooxygenase enzymes (COX-1 and COX-2), which is further metabolized into Prostaglandin E2 (PGE2). PGE2 is shown to mediate physiological functions. The educational focus of the diagram is the anti-inflammatory and anti-cancer mechanism of Betulin and Betulinic Acid. These compounds are depicted inhibiting the conversion of AA to PGH2 (indicated by a brown T-bar inhibitory symbol). Additionally, Betulin and Betulinic Acid are shown promoting apoptosis. This induced apoptosis subsequently inhibits downstream pathological processes including inflammation, cell proliferation, and angiogenesis (depicted as a complex cluster with red vascular-like tendrils). The diagram effectively visualizes how triterpenoids can interfere with the COX-2-mediated prostaglandin pathway to arrest tumor growth and reduce inflammatory responses.

A comprehensive pharmacology and pathophysiology diagram illustrating the metabolic pathways and mechanism of action of paracetamol (acetaminophen). The schematic details three primary metabolic routes in the liver: glucuronidation (via UGT) and sulfation (via SULT) producing nontoxic metabolites for renal excretion, and a cytochrome P450-mediated pathway (CYP2E1, CYP3A4) forming the toxic intermediate N-acetyl-p-benzoquinone-imine (NAPQI). It depicts the detoxification of NAPQI by glutathione (GSH) and the adverse effects of excessive NAPQI, including mitochondrial oxidation and hepatotoxicity. The diagram also shows the N-deacetylation of paracetamol to p-aminophenol, leading to the formation of AM404, which activates TRPV1, TRPA1, and CBR1/2 receptors to provide analgesia. Furthermore, it illustrates the inhibition of the prostaglandin endoperoxide H synthase (PGHS) complex at the peroxidase (POX) site, preventing the conversion of PGG2 to PGH2, thereby explaining the drug's antipyretic and analgesic effects. Target receptors such as TRPV4 are also noted as potential sites of pharmacological interaction.

This Comparison Chart displays three 1H nuclear magnetic resonance (NMR) spectra illustrating the metabolic transformation of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), at pH 5.0. Spectrum (a), shown in green, represents the initial diclofenac control with characteristic aromatic proton signals between 6.5 and 7.6 ppm. Spectrum (b), in red, shows diclofenac after interaction with sol-gel encapsulated Lignin Peroxidase (LiP). Spectrum (c), in blue, shows the result after interaction with sol-gel encapsulated Horseradish Peroxidase (HRP). The comparative analysis highlights the appearance of new, low-intensity 'artifact' peaks between 7.3–7.4 ppm and at 7.55 ppm in spectra (b) and (c). These spectral changes indicate the enzymatic formation of hydroxy-substituted derivatives and metabolites. The diagnostic focus is on evaluating the efficacy of enzymatic composites for pharmacological waste removal and metabolic profiling. The graphic demonstrates key concepts in pharmacology and medicinal chemistry, specifically the oxidative degradation pathways of drugs by peroxidase enzymes.

This diagnostic graphic displays five stacked 1H-NMR (Proton Nuclear Magnetic Resonance) spectra in the chemical shift range of 6.5–8 ppm, illustrating molecular interactions between the anti-inflammatory drug diclofenac sodium (DS), bovine submaxillary mucin (BSM), and two polysaccharides: arabinogalactan (AG) and hyaluronic acid (HA). The bottom spectrum (black line) shows pure DS with sharp, well-resolved multi-peak signals. The second spectrum (red line, DS/BSM) demonstrates significant peak broadening and decreased resolution, indicating DS immobilization via mucin interaction. The third spectrum (blue line, quaternary mixture AG/HA = 1/1) shows further broadening. In contrast, the top two spectra (green and purple lines, representing AG/HA ratios of 3/1 and 4/1) exhibit progressive peak sharpening and resolution recovery. This visual data evaluates the mucoadhesive properties and displacement capacity of AG/HA mixtures for ophthalmic drug delivery systems, specifically for treating dry eye syndrome. The sharpening of the DS peaks at higher AG ratios suggests that the polysaccharide mixture effectively displaces the drug from mucin, increasing the free drug fraction.